POC Test Based on Quantum Dots Detects Antibody Responses
By LabMedica International staff writers Posted on 31 Oct 2019 |
Image: The Holomics Reader HRDR-300 mobile device was used to measure fluorescent intensity of the quantum dots complex after lateral migration of patient serum (Photo courtesy of Medical College of Georgia).
Point-of-care (POC) assays, which can be performed at or near the site of care with a rapid turnaround time, are pivotal to transforming global disease control efforts, particularly in resource-constrained settings where access to laboratory facilities is limited.
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Latest Microbiology News
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results